Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

$HSKA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $HSKA alert in real time by email

LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021.

Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion of the business, including the acquisition of a significant part of the Fort Dodge Animal Health product portfolio as well as the acquisition and integration of the Sanofi/Merial animal health units. Dr. Hasenmaier received his Doctor of Veterinary Medicine degree from the University of Munich and his MBA from the Kellogg School of Management at Northwestern University. Dr. Hasenmaier also serves as a Director of Invetx, a pioneer in protein-based therapeutics for animal health.

"I have known and admired Joachim for years," said Kevin Wilson, the Company's Chief Executive Officer and President. "Joachim has deep expertise at the very top of the animal health market; he has led large multi-national teams, delivered impressive organic growth, engineered powerful acquisitions and partnerships, and executed complex integrations. Today, Heska gains the benefit of his extraordinary experience and relationships, which, when combined with his global and cultural perspectives, will add tremendous value to our strategic execution from our longtime U.S. and new Germany based headquarters. In a global animal health market in which diagnostics and data sit at the center of pharmaceutical, diet, and healthcare services success, Joachim can help Heska build key bridges. He is an excellent addition to Heska's already very strong Board of Directors, and I'm thrilled to welcome him."

"I am honored to join the Heska team," commented Dr. Hasenmaier. "I have long respected Heska and their commitment to drive innovation for the betterment of veterinarians and their pet patients worldwide. Heska's central position within the global diagnostics market and its ability to expand rapidly in such a competitive landscape is rare and exciting. I look forward to working with Kevin and his executive team and the Company's Board of Directors to continue Heska's upward trajectory on behalf of shareholders and employees and for the overall benefit of pets, pet owners, veterinarians, and the broader animal health industry."

About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.

SOURCE Heska Corporation

Related Links

http://www.heska.com

Get the next $HSKA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSKA

DatePrice TargetRatingAnalyst
1/6/2023$58.00Equal-Weight → Underweight
Morgan Stanley
3/1/2022$190.00 → $161.00Equal-Weight
Morgan Stanley
2/23/2022$300.00 → $250.00Overweight
JP Morgan
1/6/2022$210.00Overweight
Piper Sandler
11/18/2021$190.00Equal-Weight
Morgan Stanley
8/4/2021$240.00 → $305.00Overweight
Piper Sandler
7/12/2021$280.00Neutral → Buy
Guggenheim
More analyst ratings

$HSKA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

    Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

    NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

    $DRI
    $EXPI
    $HSKA
    $PRVA
    Restaurants
    Consumer Discretionary
    Real Estate
    Finance
  • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

    Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSKA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSKA
SEC Filings

See more

$HSKA
Leadership Updates

Live Leadership Updates

See more
  • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

    LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
Financials

Live finance-specific insights

See more
  • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

    Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

    LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Heska Corporation Completes Acquisition of LightDeck Diagnostics

    LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more